



4Q25 Earnings Release

February 11th, 2026

본 자료는 한국채택국제회계기준(K-IFRS)에 따라 작성한 휴젤 주식회사의 연결재무실적입니다.

본 자료에 포함된 재무실적 및 영업성과는 투자자 편의를 위하여 외부감사인의 감사가 완료되지 않은 상태에서 작성된 것으로 향후 외부감사인의 감사결과에 따라 변경될 수 있음을 양지하시기 바랍니다.

The financial information in this document are consolidated earnings results based on K-IFRS.

This document is provided for the convenience of investors only, before the external audit on our financial results is completed. The audit outcomes may cause some parts of this document to change.

1. 4Q25 실적 요약

4Q25 Financial Summary

(Unit: KRWbn, 십억원)

	4Q24	1Q25	2Q25	3Q25	4Q25	YoY	2025	YoY
매출액 / Net Sales	98.2	89.8	110.3	105.9	119.1	21.3%	425.1	14.0%
매출원가 / COGS	22.5	20.8	23.6	24.2	22.9	1.9%	91.6	6.6%
매출총이익 / Gross Profit	75.7	69.0	86.6	81.7	96.2	27.1%	333.5	16.1%
(%)	77.1%	76.8%	78.6%	77.1%	80.8%	3.7%p	78.5%	1.5%
판매비와관리비 / SG&A	29.3	30.1	30.0	34.3	37.6	28.5%	131.9	9.0%
영업이익 / Operating Profit	46.5	39.0	56.7	47.4	58.6	26.2%	201.6	21.3%
(%)	47.3%	43.4%	51.4%	44.8%	49.2%	1.9%p	47.4%	2.9%
법인세비용차감전순이익 / Pre-tax Income	35.3	41.1	53.3	51.1	52.1	47.5%	197.5	19.6%
순이익 / Net Income	41.4	30.9	38.2	38.0	36.8	-11.0%	144.0	0.6%
(%)	42.2%	34.4%	34.7%	35.9%	30.9%	-11.2%p	33.9%	-4.5%
지배기업 소유주지분 / Net Income from Controlling Interests	40.0	29.1	36.4	36.8	35.7	-10.7%	138.0	1.6%

2. 4Q25부문별 매출의 전년동기대비 성장률 4Q25 Sales YoY Growth Rate by Segment

보툴리눔 독신 Botulinum Toxin

+35%
(60% Mix)

 **Botulax®**
Botulinum Toxin Type A

 **Letybo®**

필러 & 스킨부스터 Filler & Skinbooster

-3%
(26% Mix)

THE CHAUM®
— 히알루론산필러 더채움® —

REVOLAX™

BYRYZN

코스메틱 및 기타 Cosmetics & Others

+27%
(14% Mix)

WELLAGE
CLINICAL DERMA FOR SKIN WELLNESS

BY
BYRYZN

**blue
rose**

Licellvi

HUGEL


+21%

Korea Sales
-4%
(32% Mix)

International Sales
+39%
(68% Mix)

3. 지역별 독신 & 필러 합산 매출의 전년동기대비 성장률 Sales YoY Growth Rate of Toxin & Filler by Region

지역별 독신 & 필러 합산 매출 Regional Toxin & Filler Sales	십억원, (%) KRWbn, (%)
국내 / Korea	25.0 (24%)
아시아 태평양 / APAC	33.0 (32%)
북남미 / North & South America	29.2 (29%)
유럽 및 기타 / EU & Others	15.3 (15%)
합계 / Total	102.6 (100%)



4. Appendix: Revenue Breakdown (4Q25)

부문별 / By Segment

(Unit: KRWbn, 십억원)

	4Q24	1Q25	2Q25	3Q25	4Q25	YoY	2025	YoY
Botulinum Toxin	53.2	40.7	61.2	60.2	71.6	34.5%	233.8	15.0%
Filler & Skinbooster	31.9	34.4	34.1	30.2	30.9	-3.1%	129.7	1.7%
Cosmetics & Others	13.0	14.7	14.9	15.5	16.6	27.2%	61.6	45.9%
Total	98.2	89.8	110.3	105.9	119.1	21.3%	425.1	13.9%

지역별 / By Region

(Unit: KRWbn, 십억원)

	Toxin & Filler							
	4Q24	1Q25	2Q25	3Q25	4Q25	YoY	2025	YoY
Korea	28.5	26.7	25.5	17.8	25.0	-12%	94.9	-14.5%
International	56.7	48.5	69.8	72.6	77.6	37%	268.5	22.2%
Asia Pacific	37.4	30.2	41.8	36.1	33.0	-12%	141.1	9.7%
North & South America	7.1	3.8	13.4	21.5	29.2	309%	67.9	105.1%
EU & Others	12.1	14.5	14.6	15.1	15.3	26%	59.5	2.6%
Total	85.2	75.2	95.3	90.4	102.6	20%	363.5	9.9%

*아시아 태평양: 중국, 태국, 호주 및 기타 아시아 국가 포함
유럽 및 기타: 유럽 및 기타 국가 포함
북남미: 브라질, 캐나다 및 기타 LATAM 국가 포함

*Asia Pacific: including China, Thailand, Australia and other Asian countries
EU & Others: including EU and other international countries
North & South America: including Brazil, Canada, and other LATAM countries

End of Document

Contact point
ir@hugel.co.kr